Mandate

Acquisition of Alvedon approved

April 07, 2009

The Swedish Competition Authority has, following an in-depth investigation, on 3 April 2009 cleared GlaxoSmithKline’s acquisition of a portfolio of drugs, including i.a. the brand Alvedon, from AstraZeneca.

Alvedon is the leading painkiller brand in Sweden. GlaxoSmithKline controlled already prior to the acquisition Panodil, one of the main competing brands. The transaction was notified by the parties on 22 December 2008.
The Competition Authority carried out an extensive market investigation and retained external expertise to simulate the effects of the combination.

“Although the transaction involved a strong market position in painkillers based on paracetamol, the Competition Authority could eventually conclude that the transaction did not significantly impede the existence or development of effective competition. The Competition Authority’s decision is, of course, satisfactory for the parties but also of principle importance”, says Johan Karlsson, responsible partner for Vinge’s competition team, who acted for AstraZeneca.

“It is one of the few cases where efficiencies made a real difference for the outcome. The decision also shows that the Competition Authority, which it should do, could also take into account future changes in the market place, in this case the liberalization of the pharmaceutical market.”

Vinge advised AstraZeneca. Vinge’s competition team included Johan Karlsson (responsible partner), Mattias Ganslandt (economist), Per Karlsson (counsel), Peter Alstergren (associate) and Carl Johan Sundqvist (associate).   

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025